A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis

Inclusion Criteria

• Diagnosis of MS made at least 3 months prior to based McDonald or Proser criteria.
• Age 18-75 years old inclusive.
• Expanded Disability Status Scale (EDS) 0-6.5
• Clinical stability defined as no MS exacerbation or change in disease modifying therapy for 60 days prior to screening.
• Screening 6-minute walking test distance between 50m-500m, inclusive.
• Written informed consent.

Exclusion Criteria

• use of 4-aminopyridine within 6 months of screening
• Any contraindication to DER:
• Allergy to DER
• history of seizure disorder or history of EEG showing epileptiform activity
• Renal insufficiency (estimated GFR 170, or systolic blood pressure > 105.
• Use of oxygen at home for 24 hours/day or severe lung disease.
• History of ventricular arrhythmia or finding of significant ventricular arrhythmia. atrial arrhythmia or 2nd or 3rd degree heart block on screening ECG.
• Concomitant neurological disease, such as ALS, Parkinson Disease, stroke.
• Hospitalization in the last 6 months for psychiatric illness.
• Alcohol or drug abuse within the past year.
• Females who are breast-feeding, pregnant or have potential to become pregnant during the course of the study( fertile and unwilling/unable to use effective contraceptive measures)
• Cognitive deficits that would interfere with the subject's ability to give informed consent or preform study testing.
• Any other serious and/or unstable medical condition.
• Use of mitoxantrone (Novantrone) within 6 months of baseline visit.